Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

Rhea-AI Summary

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced that CEO Anish Bhatnagar will participate in a fireside chat at the Guggenheim Healthcare Talks on April 3, 2023, at 10:10 AM Eastern Time. This event focuses on genomic medicines and rare diseases. Investors can access a live audio webcast as well as a replay of the discussion on the company's website. Soleno is actively developing innovative therapies for rare diseases, particularly its lead candidate, DCCR extended-release tablets, targeting Prader-Willi syndrome, which is in Phase 3 clinical trials.

REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.

A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

What is the date and time of the Soleno Therapeutics fireside chat?

The Soleno Therapeutics fireside chat is scheduled for April 3, 2023, at 10:10 AM Eastern Time.

Where can I watch the Soleno Therapeutics fireside chat?

The fireside chat can be viewed on the Investors section of Soleno Therapeutics' website.

What is the focus of the Guggenheim Healthcare Talks that Soleno is participating in?

The Guggenheim Healthcare Talks focus on genomic medicines and rare diseases.

What is Soleno Therapeutics developing for Prader-Willi syndrome?

Soleno Therapeutics is developing DCCR extended-release tablets for the treatment of Prader-Willi syndrome.

What clinical stage is Soleno's lead candidate currently in?

Soleno's lead candidate is currently in a Phase 3 clinical development program.